anti-Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Antikörper

PCSK9 encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. Zusätzlich bieten wir Ihnen PCSK9 Proteine (55) und PCSK9 Kits (34) und viele weitere Produktgruppen zu diesem Protein an.

Alle Antikörper anzeigen Gen GeneID UniProt
PCSK9 255738 Q8NBP7
PCSK9 100102 Q80W65
PCSK9 298296 P59996
Direkt bei antikoerper-online bestellen
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Online bestellen
  • orders@antikoerper-online.de

Top anti-PCSK9 Antikörper auf antikoerper-online.de

Showing 10 out of 165 products:

Katalog Nr. Reaktivität Wirt Konjugat Applikation Bilder Menge Lieferzeit Preis Details
Human Ziege Unkonjugiert ELISA, WB ABIN185371 staining (0.2 µg/mL) of McA cell lysates: untransfected (1), transfected with wild type human pcsk9 (2), transfected with S127R human pcsk9 (3). Data kindly provided by Dr. X-M Sun, Hammersmith Hospital, London. ABIN185371 (0.3 µg/mL) staining of Human Adipose lysate (35 µg protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence. 100 μg 6 bis 7 Tage
$429.84
Details
Human Kaninchen Unkonjugiert IHC (p), WB Anti-PCSK9 antibody, IHC(P) IHC(P): Human Intestinal Cancer Tissue 100 μg 4 bis 6 Tage
$280.00
Details
Human Ziege Unkonjugiert ELISA, WB   100 μg 6 bis 7 Tage
$429.84
Details
Human Kaninchen Unkonjugiert IHC (p), WB 100 μg 2 bis 3 Tage
$325.00
Details
Human Ziege Unkonjugiert EIA, WB HEK293 lysate (10 µg protein in RIPA buffer) overexpressing Human PCSK9 with C-terminal MYC tag probed with AP22408PU-N (1 µg/ml) in Lane A and probed with anti-MYC Tag (1/1000) in lane C. Mock-transfected HEK293 probed with AP22408PU-N (1mg/ml) in Lane B. Primary incubations were for 1 hour. Detected by chemiluminescence. 0.1 mg 6 bis 8 Tage
$445.50
Details
Human Kaninchen Unkonjugiert EIA, WB Western blot analysis of PCSK9 Antibody (N-term) in Jurkat cell line lysates (35ug/lane). PCSK9 (arrow) was detected using the purified Pab. 0.4 mL 6 bis 8 Tage
$484.00
Details
Human Kaninchen Unkonjugiert ICC, IHC, WB Used in DAB staining on fromalin fixed paraffin- embedded liver cancer tissue 100 μg 15 bis 18 Tage
$350.00
Details
Human Ziege Unkonjugiert ELISA, WB 100 μg 11 bis 14 Tage
$610.50
Details
Human Ziege Unkonjugiert EIA, WB HEK293 lysate (10 µg protein in RIPA buffer) overexpressing Human PCSK9 with C-terminal MYC tag probed with AP22407PU-N (0.5 µg/ml) in Lane A and probed with anti-MYC Tag (1/1000) in lane C. Mock-transfected HEK293 probed with AP22407PU-N(1mg/ml) in Lane B. Primary incubations were for 1 hour. Detected by chemiluminescence. 0.1 mg 6 bis 8 Tage
$445.50
Details
Human Kaninchen Unkonjugiert IHC, WB Western blot analysis of extracts of SW480 cells, using PCSK9 Antibody. Immunohistochemistry of paraffin-embedded rat kidney using PCSK9 antibody. 200 μL 12 bis 14 Tage
$438.90
Details

Am meisten referenzierte anti-PCSK9 Antikörper

  1. Human Polyclonal PCSK9 Primary Antibody für ChIP, IHC (p) - ABIN268772 : Cohen, Pertsemlidis, Kotowski, Graham, Garcia, Hobbs: Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. in Nature genetics 2005 (PubMed)
    Show all 12 Pubmed References

  2. Human Polyclonal PCSK9 Primary Antibody für ELISA, WB - ABIN547416 : Sun, Eden, Tosi, Neuwirth, Wile, Naoumova, Soutar: Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia. in Human molecular genetics 2005 (PubMed)

  3. Human Polyclonal PCSK9 Primary Antibody für ELISA, IP - ABIN4347755 : Lalanne, Lambert, Amar, Chétiveaux, Zaïr, Jarnoux, Ouguerram, Friburg, Seidah, Brewer, Krempf, Costet: Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells. in Journal of lipid research 2005 (PubMed)

  4. Human Polyclonal PCSK9 Primary Antibody für ELISA, WB - ABIN4347756 : Kwon, Lagace, McNutt, Horton, Deisenhofer: Molecular basis for LDL receptor recognition by PCSK9. in Proceedings of the National Academy of Sciences of the United States of America 2008 (PubMed)

  5. Human Polyclonal PCSK9 Primary Antibody für IF (p), IHC (p) - ABIN761831 : Jia, Song, Yang, Ma, Li, Lu, Cao, Zhang, Zhu, Wang, Leng, Cao, Du, Xu: Effects of Tanshinone IIA on the modulation of miR‑33a and the SREBP‑2/Pcsk9 signaling pathway in hyperlipidemic rats. in Molecular medicine reports 2016 (PubMed)

Weitere Antikörper gegen PCSK9 Interaktionspartner

Human Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Interaktionspartner

  1. Abnormal high expression of PCSK9 in the blood, liver and ovary may be involved in the pathogenesis of PCOS by affecting lipid metabolism and ovarian function.

  2. adult carriers of the less frequent T allele of the R46L variant of the PCSK9 gene have a reduced intima-media thickness and a lower prevalence of erectile dysfunction, without differences in the LDL-cholesterol levels.

  3. Circulating PCSK9 concentrations are not associated with the severity of liver steatosis or histological markers of NASH, which supports the use of PCSK9 inhibitors in cardiovascular diseases

  4. Studied genetic association of proprotein convertase subtilisin/kexin type 9 (PCSK9) variants and risk of coronary disease(CHD) and ischemic stroke (IS); found PCSK9 genetic variants that produce lower levels of LDL-C and are associated with lower risk of CHD, and a significantly lower effect, if any, on the risk of IS.

  5. In cohort of community-dwelling Black adults PCSK9 loss-of-function (LOF) variants are not associated with increased risk of hospitalization for a serious infection. Among those hospitalized for a serious infection, PCSK9 LOF variants was not associated with odds of sepsis.

  6. Study showed that plasma PCSK9 concentrations increase transiently over time in septic and non-septic critically ill patients and demonstrated that PCSK9 negatively regulates LDLR-mediated uptake of bacterial lipoteichoic acid (LTA) and lipopolysaccharide (LPS) by HepG2 hepatocytes through a lipoprotein (LDL)-dependent mechanism, whereas LRP1 and high-density lipoprotein do not contribute to this uptake pathway.

  7. In patients with potential familial hypercholesterolemia, positive correlations between concentrations of Lp(a) and PCSK9, as well as of Lp(a)-PCSK9 plasma complex with large subfractions of intermediate and low-density lipoproteins (IDL-1 and LDL-C), were determined by the low molecular weight apo(a) phenotype.

  8. rare variants in LDLR and PCSK9 were associated with the onset age of MI by altering LDL-cholesterol levels

  9. Acute-phase plasma PCSK9 levels are associated with levels of inflammation and triglycerides, premature coronary heart disease, and gender in acute myocardial infarction patients without reperfusion therapy. However, it does not predict recurrent cardiovascular events at 1 year.

  10. Thus, it is evident that sauchinone reduces hepatic steatosis by downregulating the expression of hepatic PCSK9 via SREBP-2.

  11. PCSK9 plays a role lipoprotein metabolism and atherosclerotic cardiovascular disease. Review.

  12. in patients with acute myocardial infarction, plasma PCSK9 levels measured during the acute phase predict recurrent cardiovascular events within 1 year

  13. The results of the current meta-analysis for the first time indicated the relevance of rs562556 of PCSK9 and lower serum cholesterol levels.

  14. Associations for BCO2, PCSK9, and TR1B1 Polymorphism and Lifestyle Factors with Ischemic Stroke

  15. PCSK9 association with intestinal secretion and plasma overaccumulation of TRL apoB-48 in men with IR

  16. PCSK9 may regulate LOX-1 mediated ox-LDL uptake by the THP-1 derived macrophage via TLR4/NF-kappaB/COX-2/ROS pathway

  17. Pathogenic mutations in LDLR, APOB, PCSK9 and LDLRAP1 genes were found in 17 of 225 patients with familial hypercholesterolemia leading to premature myocardial infarction.

  18. Variants at the PCSK9 gene locus seem to be the major genetic determinants of plasma PCSK9 levels.

  19. Elevated serum level of PCSK9 can be observed in systemic lupus erythematosus patients, especially in those with thickening of carotid intima-media.

  20. Identification and in vitro characterization of two new PCSK9 Gain of Function variants found in patients with Familial Hypercholesterolemia.

Mouse (Murine) Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Interaktionspartner

  1. PAQR3 plays a pivotal role in controlling hepatic LDLR degradation and blood LDL-C level via modulating LDLR-PCSK9 interaction.

  2. the serum PCSK9 protein level was significantly increased in PCOS mice (P=0.0002), which positively correlated with serum LDL-C (r =0.5279, P=0.0004) and TC (r=0.4151, P=0.035). In both liver and ovary of PCOS mice.

  3. Glucagon-Gcgr-Epac2-Rap1 pathway regulates plasma LDL-C metabolism by controlling PCSK9 degradation.

  4. PCSK9 is up-regulated in the ischaemic hearts and determines development of infarct size, cardiac function, and autophagy.

  5. In an inflammatory milieu, elevated levels of PCSK9 potently stimulate the expression of scavenger receptors (principally LOX-1) and ox-LDL uptake in macrophages, and thus contribute to the process of atherogenesis.

  6. The absence of PCSK9 in LDb mice results in decreased lipid and apoB levels, fewer atherogenic LDLs, and marked reduction of atherosclerosis.

  7. In this study, the appropriate virus-like particle (VLP)-peptide vaccines targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) were screened...PCSK9Qbeta-003 vaccine obviously decreased plasma total cholesterol in both Balb/c mice and LDLR(+/-) mice

  8. In the present study, it was investigated whether ticagrelor reduces oxidized lowdensity lipoprotein (oxLDL)induced endothelial cell apoptosis, an initial step for the development of atherosclerosis(AS), and alleviates AS in apolipoproteinEdeficient (ApoE/) mice by inhibiting the expression of proprotein convertase subtilisin/kexin type 9 (PCSK9)

  9. We observed long-term postnatal persistence of edited cells in both models, with reduction of plasma PCSK9 and cholesterol levels following in utero Pcsk9 targeting and rescue of the lethal phenotype of hereditary tyrosinemia type 1 following in utero Hpd targeting

  10. High PCSK9 expression is associated with atherosclerosis and liver cancer.

  11. Given that overexpression of these LOF PCSK9 variants does not cause UPR activation under normal homeostatic conditions, therapeutic strategies aimed at blocking the autocatalytic cleavage of PCSK9 in the ER represent a viable strategy for reducing circulating PCSK9

  12. Data suggest that expression of Pcsk9 and Ldlr in liver and pancreas can be regulated by dietary measures; here, dietary supplementation with quercetin-3-glucoside modulates expression of Pcsk9 and Ldlr in prevention of hyperlipidemia and hyperinsulinemia induced by high dietary cholesterol. (Pcsk9 = proprotein convertase subtilisin/kexin type-9; Ldlr = low-density lipoprotein receptor)

  13. The data of the present study demonstrated that the PCSK9 shRNAmediated antiapoptotic effect induced by MCAO in hyperlipidemic mice is associated with ApoER2 downregulation, which may be a potential new therapy for stroke treatment in patients with hyperlipidemia.

  14. It was concluded that quercetin inhibits oxLDLinduced lipid droplets in RAW264.7 cells by upregulation of ABCAl, ABCG1, LXRalpha and downregulation of PCSK9, p53, p21 and p16.

  15. PCSK9 overexpression in the aorta may promote acute aortic dissection.

  16. Genetically determined PCSK9 deficiency might be associated with ectopic fat accumulation.

  17. The present study aimed to explore the direct toxicity of proprotein convertase subtilisin/kexin type 9 (PCSK9) to atherosclerosis (AS) and its association with apoptotic endothelial cells.

  18. present anti-PCSK9 vaccine induced long-lasting anti-PCSK9 antibody production and improved lipoprotein profiles. Thus, anti-PCSK9 vaccine could become a new option for the treatment of dyslipidemia as a long-acting therapy in future

  19. PCSK9 may act as an inflammatory mediator in the pathogenesis of atherosclerosis via TLR4/NF-kappaB signaling pathway.

  20. PCSK9, by sustaining smooth muscle cell synthetic phenotype, proliferation, and migration, may play a pro-atherogenic role in the arterial wall

Pig (Porcine) Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Interaktionspartner

  1. the PCSK9-gain-of-function mutation induces rapid development of atherosclerosis in peripheral vessels of Ossabaw pigs, which is exacerbated by a high-cholesterol diet.

PCSK9 Antigen-Profil

Protein Überblick

This gene encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. The encoded protein is synthesized as a soluble zymogen that undergoes autocatalytic intramolecular processing in the endoplasmic reticulum. The protein may function as a proprotein convertase. This protein plays a role in cholesterol homeostasis and may have a role in the differentiation of cortical neurons. Mutations in this gene have been associated with a third form of autosomal dominant familial hypercholesterolemia (HCHOLA3).

Genbezeichner und Symbole assoziert mit PCSK9

  • proprotein convertase subtilisin/kexin type 9 L homeolog (pcsk9.L) Antikörper
  • proprotein convertase subtilisin/kexin type 9 (pcsk9) Antikörper
  • proprotein convertase subtilisin/kexin type 9 (PCSK9) Antikörper
  • proprotein convertase subtilisin/kexin type 9 (Pcsk9) Antikörper
  • AI415265 Antikörper
  • AI747682 Antikörper
  • FH3 Antikörper
  • HCHOLA3 Antikörper
  • LDLCQ1 Antikörper
  • NARC-1 Antikörper
  • Narc1 Antikörper
  • PC9 Antikörper

Bezeichner auf Proteinebene für PCSK9

proprotein convertase subtilisin/kexin type 9 , convertase subtilisin/kexin type 9 preproprotein , neural apoptosis regulated convertase 1 , subtilisin/kexin-like protease PC9 , NARC-1 , convertase subtilisin , neural apoptosis-regulated convertase 1 , proprotein convertase 9 , proprotein convertase PC9 , proprotein convertase subtilisin/kexin type 9 preproprotein , Proprotein convertase 9 , Subtilisin/kexin-like protease PC9

GENE ID SPEZIES
495509 Xenopus laevis
100150316 Danio rerio
100544916 Meleagris gallopavo
255738 Homo sapiens
100102 Mus musculus
298296 Rattus norvegicus
424664 Gallus gallus
100731533 Cavia porcellus
717147 Macaca mulatta
100971792 Pan paniscus
456880 Pan troglodytes
100395116 Callithrix jacchus
100620501 Sus scrofa
Ausgewählte Anbieter für anti-PCSK9 (PCSK9) Antikörper
Haben Sie etwas anderes gesucht?